Ankyra Therapeutics Presents Preliminary Phase 1 Canine Clinical Data Evaluating cANK-101 to Treat Advanced Malignant Melanoma in Dogs
Retrieved on:
Saturday, October 14, 2023
Oncology, Health, Clinical Trials, Pharmaceutical, Biotechnology, Veterinary, NanoString Technologies, Doctor of Philosophy, Aluminium, Tumor microenvironment, Drug development, Trial of the century, Aes, MD, H. Lee Moffitt Cancer Center & Research Institute, Melanoma, Champaign–Urbana metropolitan area, Veterinary medicine, Safety, University, Administration, Cancer, Therapy, Collection, University of Illinois College of Veterinary Medicine, Data, Associate, Dog, Illinois College, Translation, Interleukin, DVM, Macrophage, Human, Vaccine
Ankyra Therapeutics, a pre-clinical stage biotechnology company developing a new class of anchored immunotherapies to treat cancer, today presented preliminary data from an exploratory Phase 1 canine clinical study evaluating cANK-101, a canine IL-12 anchored therapeutic, to treat advanced malignant melanoma.
Key Points:
- Ankyra Therapeutics, a pre-clinical stage biotechnology company developing a new class of anchored immunotherapies to treat cancer, today presented preliminary data from an exploratory Phase 1 canine clinical study evaluating cANK-101, a canine IL-12 anchored therapeutic, to treat advanced malignant melanoma.
- Fan demonstrated the safety, tolerability, and activity of cANK-101 in dogs (n=10) with advanced malignant melanoma and will inform the design of future human clinical trials.
- “The continued collection of data on cANK-101 in dogs with advanced malignant melanoma provides us confidence in the efficacy, safety, and tolerability profile of this novel compound,” said Dr.
- “The noticeable increase in downstream cytokines that trigger an immune response in dogs with melanoma mean that there may be new drug development opportunities to impact clinical outcomes for companion dogs.”